Scrip
Hopes high for Provenge to become first US-approved therapeutic cancer vaccine
01 May 2009
Malini Guha
Please Login to read the full article.
01 May 2009
Malini Guha
Dendreon's closely watched novel cancer therapy Provenge (sipuleucel-T) could become the first targeted therapeutic cancer vaccine to be approved in the US after it improved median overall survival by about four months to almost 26 months in men with advanced, hormone-refractory (androgen-independent)...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Dendreon's Provenge becomes first therapeutic cancer vaccine to be approved in US
- Sanofi-Aventis's new chemotherapy drug Jevtana improves survival in advanced prostate cancer
- Avastin fails only Phase III trial in advanced prostate cancer
- Dendreon to raise up to $448 million to fund Provenge commercialisation
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
